Hepatitis B Surface Antibody Negative: Interpretation and Management

Introduction to Hepatitis B Interpretation

A negative hepatitis B surface antibody (anti-HBs) result indicates a lack of immunity to hepatitis B virus, meaning the patient is susceptible to HBV infection and requires further evaluation to determine their complete HBV status and need for vaccination, according to the American College of Physicians 1

A full hepatitis B panel, including HBsAg, anti-HBc, and anti-HBs, is necessary to interpret the negative anti-HBs result properly, as recommended by the Centers for Disease Control and Prevention 2
The presence of anti-HBc indicates past or current exposure to HBV, as stated by the World Health Organization 3, 2

If HBsAg is negative, anti-HBc is negative, and anti-HBs is negative, the patient has never been infected with HBV and is susceptible to infection, requiring immediate hepatitis B vaccination series, as indicated by the American Academy of Family Physicians 2, 1
If HBsAg is positive and anti-HBs is negative, the patient has active hepatitis B infection, which may be acute or chronic, and requires further testing and potential specialist referral, according to the European Association for the Study of the Liver 2

Patients who are anti-HBc positive but anti-HBs negative have a high risk of HBV reactivation (up to 68.3% with rituximab-based chemotherapy) compared to those with anti-HBs present, as reported by the American Gastroenterological Association 4
The American Society of Clinical Oncology recommends obtaining HBV DNA level before starting immunosuppression and initiating antiviral prophylaxis with nucleos(t)ide analogues regardless of HBV DNA level if receiving high-risk immunosuppression 3, 4

The Centers for Disease Control and Prevention recommends that healthcare workers and those with ongoing HBV exposure risk require periodic testing, including hepatitis B surface antibody screening 1
The National Kidney Foundation suggests that dialysis patients may need annual anti-HBs screening even if previously immune, to monitor for potential loss of immunity 1
The American College of Obstetricians and Gynecologists notes that pregnant women with resolved HBV (anti-HBc positive) may experience postpartum flares, highlighting the need for close monitoring 4

A reactive hepatitis B core antibody (HBcAb) with negative hepatitis B surface antigen (HBsAg) indicates past hepatitis B infection with viral clearance, but this serologic pattern carries a significant risk of HBV reactivation (3% to 45%) if the patient undergoes immunosuppressive therapy, particularly with anti-CD20 monoclonal antibodies like rituximab, as recommended by the National Comprehensive Cancer Network 5

Patients with HBcAb positivity face substantial reactivation risk when receiving anti-CD20 monoclonal antibodies (rituximab, ofatumumab), with reactivation rates of 3% to 45% in HBcAb-positive patients, as documented by the National Comprehensive Cancer Network 5, 6
The presence of anti-HBs (hepatitis B surface antibody) alongside HBcAb positivity generally indicates better immune control and lower reactivation risk, though reactivation can still occur with significant immunosuppression, according to the National Comprehensive Cancer Network 5, 6

The National Comprehensive Cancer Network recommends initiating antiviral prophylaxis before starting immunosuppression in patients receiving rituximab-containing regimens or intensive chemotherapy, and continuing prophylaxis for 6 to 12 months after completing immunosuppressive therapy 5, 6
Entecavir or tenofovir are preferred agents for antiviral prophylaxis due to lower resistance rates compared to lamivudine, as recommended by the National Comprehensive Cancer Network 5
Prophylactic antiviral therapy is more effective in preventing reactivation than deferred therapy, with 0% reactivation versus 53% with deferred therapy, according to the National Comprehensive Cancer Network 5